Interpace Diagnostics Signs an AI-Driven Agreement with Predictive Oncology for Diagnosing Thyroid Cancer
Shots:
- The companies will develop a pipeline of products used for diagnosing and assessing the risks of thyroid cancer- leveraging Interpace’s ThyGeNEXT and ThyraMIR assays combining with Helomics’ patient-derived tumor profiling and AI platform- D-CHIP
- Helomics to build a model utilizing Interpace’s clinical data which can be further used in identifying targets for treating indolent and aggressive thyroid cancers
- ThyGeNEXT and ThyraMIR is a next generation sequencing and proprietary gene expression assay respectively for identifing 150+ genetic alterations associated with thyroid cancer from thyroid nodules
Click here to read full press release/ article | Ref: Interpace Diagnostics | Image: Behnace
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com